



Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

January 7, 2025

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway -
- Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) -
- Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled across all three Phase 2a pancreatic arms -
- Continued highly differentiated tolerability profile observed for IMM-1-104; approved MEK inhibitors currently drive ~\$2.4 billion in sales -
- Further IMM-1-104 Phase 2a data expected in 2Q'25; additional combination arms planned to be initiated in 2025 -
- Company to hold webcast today at 8.30 am ET /5:30 am PT -

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, as well as plans to expand the Phase 2a trial to include three additional combination arms. While approved MEK inhibitors mainly benefit a subset of patients with BRAF-driven tumors, IMM-1-104 was designed to improve tolerability and expand indications to include RAS-mutated tumors such as those found in most pancreatic cancers.


"We are excited to report an updated ORR of 43% and DCR of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. For reference, the benchmark reported for gemcitabine/nab-paclitaxel in this setting had an ORR of 23% and DCR of 48%. We look forward to reporting further data in the second quarter of 2025 and have started planning for a potential pivotal clinical trial," said Ben Zeskind, Ph.D., CEO of Immuneering.

Dr. Zeskind continued: "Today we are also sharing initial data from IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer patients. We observed target lesion shrinkage across all evaluable patients, including a 100% reduction, a rare event in this patient population. Additionally, we are reporting initial data from our monotherapy arm of IMM-1-104 in second-line pancreatic cancer. We saw clear activity, including a partial response with a 67% target lesion reduction. We believe these results provide substantiating evidence of IMM-1-104's contribution in combination with current therapies."

Dr. Zeskind concluded: "Importantly, we continue to observe a highly differentiated safety profile for IMM-1-104, which we designed to be better tolerated and more active than existing approved MEK inhibitors already driving annual net sales of ~\$2.4 billion in 2023. Accordingly, we plan to add three new Phase 2a combination arms: IMM-1-104 with a BRAF inhibitor in BRAF-mutant melanoma, and IMM-1-104 with an immune checkpoint inhibitor in both melanoma and NSCLC. We expect to initiate these arms in 2025. Today we are setting a path to break new ground in indications where no MEK inhibitors have been approved, including pancreatic cancer, and aim to provide a better tolerated and more effective alternative where MEK inhibitors are already helping patients."


Updated Data from Phase 2a Arm Evaluating IMM-1-104 with Modified Gemcitabine/nab-Paclitaxel in First Line Pancreatic Cancer as of December 5, 2024

Updated Data from Phase 2a Arm Evaluating IMM-1-104 with Modified Gemcitabine/nab-Paclitaxel in First Line Pancreatic Cancer as of December 5, 2024




Updated Data from Phase 2a Arm Evaluating IMM-1-104 with Modified Gemcitabine/nab-Paclitaxel in First Line Pancreatic Cancer as of December 5, 2024

Initial Data from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of December 5, 2024



Initial Data from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of December 5, 2024

Initial Data from Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second Line Pancreatic Cancer as of December 5, 2024




Initial Data from Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second Line Pancreatic Cancer as of December 5, 2024

Safety: Phase 2 Monotherapy in 2L PDAC at 320 mg QD (n=21)

Safety: Phase 2a Monotherapy in 2L PDAC at 320 mg QD (n = 21)					
Maximum Severity of TRAEs:	Grade 1	Grade 2	Grade 3	Grade 4	Any Grade
TRAEs observed in ≥10.0% of patients, n(%)					
1. Rash*	5 (24%)	1 (5%)	0	0	6 (29%)
2. Diarrhea	3 (14%)	2 (10%)	0	0	5 (24%)
3. Fatigue	3 (14%)	1 (5%)	0	0	4 (19%)
4. Nausea/Vomiting	3 (14%)	0	0	0	3 (14%)
5. Blurred Vision	2 (10%)	1 (5%)	0	0	3 (14%)

* All data as of December 5, 2024. TRAE = Treatment-Related Adverse Event
 • IMM-1-104 TRAEs above have been reversible; no TRAEs in the table above were deemed serious.
 • Patient population includes one (1) PDAC patient; all patients were above of 50 (N=20) mg QD for
 • * Preferred terms included in the table above include: Dermatitis acneiform, Photosensitivity reaction, Rash, Rash macular, Rash maculo-papular, Rash pruritic, Rash pustular

Safety: Phase 2 Monotherapy in 2L PDAC at 320 mg QD (n=21)



Observation	IMM-1-104 + mGnP
Overall Response Rate (ORR)	43%
Disease Control Rate (DCR)	86%
Complete Response (CR)	14%

All data as of December 5, 2024
 (Best Overall Response (BOR) to date Shown)

• ORR analyses included all evaluable patients who received their first dose of IMM-1-104 at least 14 weeks prior to data cutoff of December 5th, 2024 (to allow 2 potential scans beyond baseline scan – patients who had 2 such scans prior to 14 weeks were also included). Scans typically occur every 6 weeks (+/- 1 week)
 • Glossary: PD = progressive disease; PR = partial response; SD = Stable Disease; SLD = sum of longest tumor diameter; DCR = disease control rate (CR+PR+SD)


Source: Immuneering Corporation

- As of December 5, 2024, three patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer achieved complete or partial responses for an overall response rate of 43% (3/7) and disease control rate of 86% (6/7). Four patients remain on treatment.
- Benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients were established by the Phase 3 MPACT study, which included 1 Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate¹. Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel, the less intensive regimen utilized in the IMM-1-104 Phase 2 combination arm, include an 18.6% ORR².
- A favorable tolerability profile was observed for IMM-1-104 in combination with modified Gemcitabine/nab-Paclitaxel.

[1] Von Hoff, et al. N Engl J Med 2013;369:1691-1703, [2] Ahn DH, et al. Therapeutic Advances in Medical Oncology. 2017;9(2):75-82

“Immuneering’s Phase 2a data in first-line pancreatic cancer are very promising,” said Tanios Bekaii-Saab, M.D., Leader of the Gastrointestinal Cancer Disease Group for the Mayo Clinic Cancer Center enterprise-wide and Medical Oncology consultant in Mayo Clinic in Phoenix, Arizona. “If current trends continue, the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel may provide improved efficacy and tolerability versus gemcitabine/nab-paclitaxel in the first-line pancreatic cancer setting, where patients continue to urgently need better options. In addition, having a MEK inhibitor that appears to be as well-tolerated as IMM-1-104 may provide new opportunities for patients with different types of cancer.”

Initial Data from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of December 5, 2024




- Includes all evaluable patients who received their first dose of IMM-1-104 at least 14 weeks prior to data cutoff of December 5th, 2024 (to allow 2 potential scans beyond baseline scan – patients who had 2 such scans prior to 14 weeks were also included)
- Two patients with subsequently verified rare genomic variants (e.g., DPD, UGT1A1) that significantly impact ability to metabolize chemotherapy had their chemotherapy regimens dose reduced and are excluded in the analysis (both still achieved overall RECIST SLD regressions)
- (*) Patient withdrew prior to confirmatory scan or evidence of disease progression.
- (**) Patient's second scan was uPR; however, new mets observed in 3rd scan (Final BOR = SD)
- IMM-1-104 + modified FOLFIRINOX (mFFX) was observed to be generally well tolerated.

Source: Immuneering Corporation

- As of December 5, 2024, all evaluable patients (n=4) experienced target tumor shrinkage and disease control, with one patient achieving a 100% reduction (PR).
- The combination of IMM-1-104 plus modified FOLFIRINOX (mFFX) was observed to be generally well tolerated.
- The Company is currently evaluating the 320 mg QD dose of IMM-1-104 in combination with modified FOLFIRINOX.

Initial Data from Phase 2a Arm Evaluating IMM-1-104 Monotherapy in Second Line Pancreatic Cancer as of December 5, 2024



- ORR analyses included all evaluable patients who received their first dose of IMM-1-104 at least 14 weeks prior to data cutoff of December 5th, 2024 (to allow 2 potential scans beyond baseline scan – patients who had 2 such scans prior to 14 weeks were also included). Scans typically occur every 6 weeks (+/- 1 week)
- Glossary: ORR = overall response rate; CR = complete response; PD = progressive disease; PR = partial response; SD = Stable Disease; SLD = sum of longest tumor diameter; DCR = disease control rate (CR+PR+SD); BOR = best overall response

Source: Immuneering Corporation

“Having demonstrated compelling activity in both the combination and monotherapy settings for pancreatic cancer, the emerging tolerability profile for IMM-1-104 is also highly promising,” said Brett Hall, Ph.D., Chief Scientific Officer, Immuneering Corporation. “Looking at the table of treatment-related adverse events observed in greater than 10% of patients in our monotherapy arm, no Grade 3 or Grade 4 events were observed, and only a handful of Grade 2 events were observed. The maturing safety profile for IMM-1-104 gives us confidence that Immuneering may have developed a better tolerated MEK-inhibitor, with exciting potential for vertical, immune-modifying, and orthogonal combinations. We expect to share expanded development plans for IMM-1-104 beyond pancreatic cancer, as we continue to explore options with investigators and third parties.”

Safety: Phase 2a Monotherapy in 2L PDAC at 320 mg QD (n = 21)

Maximum Severity of TRAEs:	Grade 1	Grade 2	Grade 3	Grade 4	Any Grade
TRAE's observed in ≥10.0% of patients, n(%)					
1. Rash*	5 (24%)	1 (5%)	0	0	6 (29%)
2. Diarrhea	3 (14%)	2 (10%)	0	0	5 (24%)
3. Fatigue	3 (14%)	1 (5%)	0	0	4 (19%)
4. Nausea/Vomiting	3 (14%)	0	0	0	3 (14%)
5. Blurred Vision	2 (10%)	1 (5%)	0	0	3 (14%)

- All data as of December 5, 2024. TRAE = Treatment Related Adverse Event
- IMM-1-104 TRAE's above have been reversible; no TRAEs in the table above were deemed serious
- Patient population includes one 1L PDAC patient; all patients were dosed at 320 (N=21) mg QD p.o.
- (*) Preferred Terms Included in the Rash term include: Dermatitis acneiform, Photosensitivity reaction, Rash, Rash macular, Rash maculo-papular, Rash pruritic, Rash pustular

Source: Immuneering Corporation

- As of December 5, 2024, eleven of the twenty-one evaluable patients treated in the Phase 2a arm assessing IMM-1-104 as monotherapy in second-line pancreatic cancer achieved disease control, including one patient with 67% target lesion shrinkage (PR). Nine patients remain on treatment.
- IMM-1-104 monotherapy was observed to be very well tolerated in second-line pancreatic cancer patients, suggesting that IMM-1-104 may be highly suitable for both monotherapy and combination therapy.

Immuneering previously announced that IMM-1-104 received Fast Track designation from the FDA for the treatment of first- and second-line pancreatic cancer, along with orphan drug designation. The FDA also recently granted Fast Track designation for IMM-1-104 as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors. Today's data update follows initial data that was presented in September 2024 on the trial's arm studying IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.

Today, Immuneering also announced initial pharmacokinetic, pharmacodynamic and safety data from the Phase 1 portion of the company's Phase 1/2a trial of IMM-6-415. To date, IMM-6-415 has demonstrated its potential to induce Deep Cyclic Inhibition, and in doing so has been well tolerated – consistent with what was observed preclinically for the development candidate.

Near-Term Milestone Expectations

IMM-1-104

- Further IMM-1-104 Phase 2a data expected in the second quarter of 2025
- Initiation of Phase 2a arm of IMM-1-104 in combination with BRAF inhibitor in melanoma planned for 2025
- Initiation of Phase 2a arms of IMM-1-104 in combination with checkpoint inhibitors in both melanoma and NSCLC planned for 2025

Conference Call

Immuneering will host a conference call and live webcast at 8:30 a.m. ET / 5:30 a.m. PT on January 7, 2025, to discuss the data and provide a business update. Individuals interested in listening to the live conference call may do so by dialing (800) 715-9871 for U.S callers and (646) 307-1963 for other locations and reference conference ID 4497245, or from the webcast link in the "investors" section of the company's website at www.immuneering.com. A webcast replay will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective *and* better tolerated therapies for cancer patients. The Company's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company's development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering's plans to develop, manufacture and commercialize its product candidates; the treatment potential of IMM-1-104 and IMM-6-415, alone or in combination with other agents, including chemotherapy, PD-1 inhibitors and BRAF inhibitors; the future sales of approved MEK inhibitors; the plans and objectives of Company management for future operations, including with respect to the

planning and execution of additional IMM-1-104 combination trials and potential pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel; and the timing for release of additional results from the Phase 2a portion of the trial for IMM-1-104.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Media Contact:

Gina Nugent
gina@nugentcommunications.com

Investor Contact:

Laurence Watts
619-916-7620
laurence@newstreetir.com

Photos accompanying this announcement are available at

<https://www.globenewswire.com/NewsRoom/AttachmentNg/d2901d24-0359-41be-bfdd-d679a81f408a>

<https://www.globenewswire.com/NewsRoom/AttachmentNg/229da72c-b1b9-44dc-9da9-b6369e6aca91>

<https://www.globenewswire.com/NewsRoom/AttachmentNg/59285cbc-ba80-4765-9855-3701ffc9b719>

<https://www.globenewswire.com/NewsRoom/AttachmentNg/57c609d6-d102-46cf-8a15-706c93aeb8e6>